Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Speculative but catalyst-rich biotech setup: Roche collaboration brought $700M upfront and up to $2.3B in potential payments, while NX-5948 Phase 1a/b data showed 92.9% ORR in second-line post-BTK CLL/SLL patients. Shares are up about 38% over the last 20 trading days, supported by a stronger biotech tape.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Liquidity cushion ⢠Cash burn ⢠Equity erosion NRIX has strong liquidity and low debt, but its near-100% gross margin is overwhelmed by massive R&D-driven losses and cash burn, driving sharply weaker equity value.
Price Behavior
Key Price Behavior Insights: ⢠Higher-highs trend ⢠Breakout hold ⢠Stretched extension Support Level: $25.2 to $25.5 Resistance Level: $27.19 NRIX has been in a steady uptrend over the last month, with higher highs and higher lows, but it is now extended near resistance at $27.19, making a short-term pause or pullback more likely even as the broader trend remains constructive.
Sentiment & News
Key News Insights: ⢠Roche clearance ⢠Phase 3 start ⢠Analyst upgrade Nurix advanced multiple catalystsâRoche collaboration cleared HSR, Sanofi delivered a $10M milestone, and bexobrutideg entered Phase 3âhelping push the stock to a 52-week high on improved analyst sentiment.
AI Summary
NRIX now looks less like a cash-burning biotech and more like a partner-validated late-stage pipeline story, where Roche/Sanofi support and strong liquidity buy time, but the stock's real upside now depends on executing bexobrutideg's Phase 3 and other milestones without a clinical miss or further dilution pressure.
Description
Nurix Therapeutics is a biopharmaceutical company that discovers and develops small-molecule treatments for oncology and immune disorders, with an emphasis on orally administered BTK degraders and CBLâB modulators. Its pipeline includes agents for relapsed or refractory Bâcell malignancies, therapies to support adoptive Tâcell approaches, and a cell therapy candidate in Phase 1 for gynecologic cancers. The company collaborates with Gilead and Sanofi, was incorporated in 2009, and is headquartered in San Francisco, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 15 | Jul 22 | NRIX | Nurix Therapeutics, Inc. | Speculative but catalyst-rich biotech setup: Roche collaboration brought $700M upfront and up to $2.3B in potential payments, while NX-5948 Phase 1a/b data showed 92.9% ORR in second-line post-BTK CLL/SLL patients. Shares are up about 38% over the last 20 trading days, supported by a stronger biotech tape. | Closed | -1.1% |
| Jul 2 | Jul 9 | NRIX | Nurix Therapeutics, Inc. | Strong near-term catalyst and momentum setup: stock rose about 42% over 21 trading days, supported by Roche collaboration worth up to $2.3B with $700M upfront and positive NX-5948 CLL/SLL data including 92.9% ORR in a second-line group. | Closed | +3.0% |